回盛生物: 2025年半年度报告摘要

Core Viewpoint - Wuhan Huasen Biological Technology Co., Ltd. reported significant growth in revenue and profit for the first half of 2025, indicating a strong operational performance compared to the previous year [1][2]. Financial Performance - The company's operating revenue reached approximately 822.20 million yuan, an increase of 88.45% compared to 436.30 million yuan in the same period last year [1]. - Net profit attributable to shareholders was approximately 117.18 million yuan, reflecting a substantial increase of 325.88% from a loss of 51.88 million yuan in the previous year [1]. - The net cash flow from operating activities was approximately 123.85 million yuan, showing a remarkable increase of 499.41% compared to a decrease of 31.01 million yuan in the previous year [1]. - Basic and diluted earnings per share were both 0.6622 yuan, marking an increase of 311.77% from a loss of 0.3127 yuan per share in the previous year [1]. Asset and Equity Position - Total assets at the end of the reporting period were approximately 2.97 billion yuan, a decrease of 1.55% from 3.01 billion yuan [2]. - Net assets attributable to shareholders increased by 41.23% to approximately 2.06 billion yuan from 1.46 billion yuan [2]. Shareholder Information - The largest shareholder, Wuhan Tongseng Investment Co., Ltd., holds 40.92% of the shares, with a total of 82.80 million shares [2]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [3].